Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-04-08 22:30 |
Cellectis présente les données précliniques de son premier produit candidat all…
|
French | 93.6 KB | ||
| 2022-04-08 22:30 |
Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell P…
|
French | 93.6 KB | ||
| 2022-04-07 22:30 |
Monthly information on share capital and company voting rights
|
English | 90.0 KB | ||
| 2022-04-07 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 100.8 KB | ||
| 2022-03-11 22:31 |
Cellectis annonce sa participation à deux conférences investisseurs
|
French | 108.9 KB | ||
| 2022-03-11 22:30 |
Cellectis to Participate in Two Upcoming Investor Conferences in March
|
English | 99.0 KB | ||
| 2022-03-10 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 101.8 KB | ||
| 2022-03-10 22:30 |
Monthly information on share capital and company voting rights
|
English | 91.2 KB | ||
| 2022-03-03 22:45 |
Cellectis publie ses résultats financiers du quatrième trimestre 2021 et de l’e…
|
French | 307.9 KB | ||
| 2022-03-03 22:45 |
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 F…
|
English | 481.1 KB | ||
| 2022-02-24 22:36 |
Cellectis organise une conférence téléphonique pour présenter ses résultats fin…
|
French | 84.1 KB | ||
| 2022-02-24 22:35 |
Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at …
|
English | 68.8 KB | ||
| 2022-02-18 22:40 |
Calyxt annonce le placement d’actions et de bons de souscriptions d’actions pou…
|
French | 75.9 KB | ||
| 2022-02-18 22:40 |
Calyxt Announces Pricing of Offering Of Common Stock and Warrants and Updates B…
|
English | 56.7 KB | ||
| 2022-02-11 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 83.8 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
